TTM
−$2.88B
YoY change
-24.8%
5Y CAGR
—
Peak year (2021)
$13.54B
Cumulative EBITDA
$10.96B
EBITDA history chart for Moderna (MRNA) from 2016 to 2025
Latest: −$2.55B
EBITDA growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -24.8%
EBITDA history table for Moderna (MRNA) from 2016 to 2025
| 2025 | −$2.55B | -24.8% | +$841.00M | ||
| 2024 | −$3.39B | +3.4% | −$111.00M | ||
| 2023 | −$3.28B | -133.0% | −$13.23B | ||
| 2022 | $9.95B | -26.5% | −$3.58B | ||
| 2021 | $13.54B | -2024.3% | +$14.24B | ||
| 2020 | −$703.38M | +47.4% | −$226.29M | ||
| 2019 | −$477.08M | +15.8% | −$65.03M | ||
| 2018 | −$412.05M | +75.1% | −$176.72M | ||
| 2017 | −$235.33M | +12.8% | −$26.67M | ||
| 2016 | −$208.66M | — | — |
- 2025−$2.55B-24.8%
- 2024−$3.39B+3.4%
- 2023−$3.28B-133.0%
- 2022$9.95B-26.5%
- 2021$13.54B-2024.3%
- 2020−$703.38M+47.4%
- 2019−$477.08M+15.8%
- 2018−$412.05M+75.1%
- 2017−$235.33M+12.8%
- 2016−$208.66M—
EBITDA values are taken from Moderna's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's current EBITDA (TTM) is −$2.88B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Moderna (MRNA) EBITDA is −$2.55B – declined 24.8% year-over-year.
Between 2021 and 2025, Moderna EBITDA plunged 118.9%, falling from $13.54B to −$2.55B.
The record annual EBITDA stands at $13.54B, reached in 2021; the historical low of −$3.39B was recorded in 2024.
Moderna EBITDA by Year
Moderna EBITDA 2025: −$2.55B
Moderna EBITDA in 2025 was −$2.55B, declined 24.8% below 2024.
Moderna EBITDA 2024: −$3.39B
2024's EBITDA for Moderna came in at −$3.39B, edged up 3.4% from 2023. This figure represents the lowest annual value in the available history.
Moderna EBITDA 2023: −$3.28B
Moderna posted EBITDA of −$3.28B in 2023, plunged 133.0% below 2022.
Moderna EBITDA 2022: $9.95B
In 2022, Moderna reported EBITDA of $9.95B, declined 26.5% below 2021.
Moderna EBITDA 2021: $13.54B
Moderna EBITDA in 2021 was $13.54B.
See more financial history for Moderna (MRNA).
Sector peers by EBITDA
Healthcare peers of Moderna (MRNA), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation